Outcomes and Disease Management in Patients With Atrial Fibrillation ≥80 Years: Data From a Consecutive 11‐Year Real‐World Registry
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.036832 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Mustafa Yildirim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Disease Management, Stroke. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
As the population ages, atrial fibrillation (AF) prevalence increases, but data on optimal oral anticoagulation (OAC) in patients ≥80 years remain limited. This study tested whether direct OACs offer comparable benefits to vitamin K antagonists in patients ≥80 years with AF presenting to the emergency department.
Methods
This single‐center retrospective all‐comer study used data from the Heidelberg Registry of Atrial Fibrillation, including patients with AF presenting to the emergency department of the University Hospital of Heidelberg from June 2009 until March 2020. Data were analyzed by age for outcomes and risk factors for predefined end points.
Results
Patients ≥80 years comprised 32.2% of AF cases. Hazard ratios (HRs) for the primary end point (all‐cause mortality, stroke, or myocardial infarction) and secondary end point (including major bleeding) were 3.09 (95% CI, 2.73–3.21) and 2.96 (95% CI, 2.73–3.21) for patients ≥80 years, compared with younger patients. Anticoagulation rates were slightly lower in patients ≥80 years (67.9% versus 70.5%, P =0.0070). OAC use, particularly the use of direct OACs, increased over time. Patients ≥80 years without OACs had higher HRs for primary (3.48 [95% CI, 3.07–3.94]) and secondary end points (3.23 [95% CI, 2.86–3.64]) compared with those with OACs. Vitamin K antagonist use was linked to higher HR for stroke or major bleeding events (HR, 1.25 [95% CI, 1.05–1.50]), rising to 1.64 (95% CI, 1.34–2.01) after excluding reduced direct OAC doses.
Conclusions
Our data highlight patients ≥80 years as an important and vulnerable subpopulation of patients with AF, where evidence for optimal OAC therapy remains conflicting. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05995561.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
ORCID-Profile: Mustafa Yildirim, Barbara Ruth Milles, Moritz Biener, Norbert Frey, Hugo A Katus, Evangelos Giannitsis, Christian Salbach
Zitieren
APA
Yildirim, M., Milles, B. R., Hund, H., Biener, M., Müller-Hennessen, M., Frey, N., Katus, H. A., Giannitsis, E., & Salbach, C. (2025). Outcomes and Disease Management in Patients With Atrial Fibrillation ≥80 Years: Data From a Consecutive 11‐Year Real‐World Registry. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036832
Vancouver
Yildirim M, Milles BR, Hund H, Biener M, Müller-Hennessen M, Frey N, et al. Outcomes and Disease Management in Patients With Atrial Fibrillation ≥80 Years: Data From a Consecutive 11‐Year Real‐World Registry. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.036832
BibTeX
@article{Yildirim2025,
author = {Yildirim, Mustafa and Milles, Barbara Ruth and Hund, Hauke and Biener, Moritz and Müller-Hennessen, Matthias and Frey, Norbert and Katus, Hugo A and Giannitsis, Evangelos and Salbach, Christian},
title = {Outcomes and Disease Management in Patients With Atrial Fibrillation ≥80 Years: Data From a Consecutive 11‐Year Real‐World Registry},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.036832}
}
EUVIMED